UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~January 813, ~~2021~~2022

GLOBAL WHOLEHEALTH PARTNERS CORPORATION

(Exact name of registrant as specified in its charter)

Nevada	000-56035	46-2316220
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1130 Calle Cordillera

San Clemente, CA

92673

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code (714) 392-9752

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 8 - Other Events

Item 8.01 Other Events.

~~Global~~On ~~Wholehealth~~January ~~Partners~~13, ~~Corporation~~2022, (the ~~“Company”)~~Board ~~has~~of ~~established~~Directors aof ~~purchasing~~Global ~~relationship~~Wholehealth ~~with~~Partners ~~Kisso,~~Corporation ~~LLC~~ (the “~~Kisso~~Company”), declared a ~~supplier~~dividend of two ~~Emergency~~shares ~~Use~~of ~~Authorization~~common ~~(EUA)~~stock ~~antigen~~for ~~tests~~each ~~for~~one ~~COVID-19.~~share Onof ~~November~~common 8,stock ~~2021,~~of the Company ~~purchased 10~~,~~000~~ ~~boxes~~par ofvalue ~~EUA~~$0.001. ~~Approved~~The ~~COVID-19~~record ~~Home~~date ~~Test~~will ~~Kits~~be ~~from~~March ~~Kisso~~31, ~~for distribution. Sales~~2022 ~~from~~and ~~this~~the ~~purchase~~payable ~~are~~date ~~expected~~will tobe ~~generate~~April ~~revenue~~1, ~~for the Company~~2022.

On January 13, 2022, the Company issued a press release announcing the declaration of the common stock dividend, which is filed hereto as Exhibit 99.1 and incorporated herein by reference.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

Exhibit No.		Document		Location
99.1		Press release dated January 13, 2022		Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLOBAL WHOLEHEALTH PARTNERS CORPORATION (Registrant) Date: ~~November~~January 1213, ~~2021~~2022 By: /s/ Charles Strongo Charles Strongo Chief Executive Officer

Filing Compare · Global Wholehealth Partners Corp